These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37525072)

  • 1. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.
    Ebenbichler C; Drexel H; Hanusch U; Toplak H; Dhalwani NN; Bridges I; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2024 Feb; 136(3-4):77-86. PubMed ID: 37525072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
    Lehrke M; Vogt A; Schettler V; Girndt M; Fraass U; Tabbert-Zitzler A; Bridges I; Dhalwani NN; Ray KK
    Adv Ther; 2024 Mar; 41(3):1184-1200. PubMed ID: 38286961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.
    Sudano I; Krähenbühl S; Mach F; Anstett A; Dhalwani N; Bridges I; Sibartie M; Ray KK
    Ther Adv Cardiovasc Dis; 2024; 18():17539447231213288. PubMed ID: 38183273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
    Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
    Goicoechea M; Álvarez V; Segarra A; Polaina M; Martín-Reyes G; Robles NR; Escudero V; Orellana C; Bea Granell S; de Juan-Ribera J; Fernández Lucas M; Graña JM; Reque J; Sánchez Hernández R; Villamayor S; Górriz JL
    Nefrologia (Engl Ed); 2022; 42(3):301-310. PubMed ID: 36210619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study.
    Nanchen D; Carballo D; Bilz S; Rickli H; Koskinas KC; Mach F; Mueller C; Crljenica C; Rossi M; Reichert N; Sudano I
    Adv Ther; 2022 Jan; 39(1):504-517. PubMed ID: 34796465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels.
    Svensson MK; James S; Ravn-Fischer A; Villa G; Schalin L; Cars T; Gustafsson S; Hagström E
    Ups J Med Sci; 2024; 129():. PubMed ID: 38327639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
    Ray KK; Bruckert E; Peronne-Filardi P; Ebenbichler C; Vogt A; Bridges I; Sibartie M; Dhalwani N
    Atherosclerosis; 2023 Feb; 366():14-21. PubMed ID: 36696747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
    Hao Y; Yang YL; Wang YC; Li J
    Int Heart J; 2022 Jul; 63(4):669-677. PubMed ID: 35831153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy evaluation of PCSK9 monoclonal antibody (Evolocumab) in combination with Rosuvastatin and Ezetimibe on cholesterol levels in patients with coronary heart disease (CHD): A retrospective analysis from a single center in China.
    Liu Y; Han B
    Transpl Immunol; 2022 Apr; 71():101444. PubMed ID: 34375677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
    Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
    Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
    Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study.
    Barrios V; Escobar C; Arrarte V; García E; Fernández MR; Rincón LM; Roldán C
    Clin Investig Arterioscler; 2020; 32(6):231-241. PubMed ID: 32605806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.